{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:39:53Z","timestamp":1790077193288,"version":"4.0.1"},"reference-count":17,"publisher":"Georg Thieme Verlag KG","issue":"09","funder":[{"name":"International Society on Thrombosis and Haemostasis (ISTH)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>We investigated three-month clinical outcomes in patients with venous thromboembolism (VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice. Between November 2012 and February 2015, 2,062 consecutive patients with VTE from 11 acute care hospitals in Switzerland were enrolled in the SWIss Venous ThromboEmbolism Registry (SWIVTER). Overall, 417 (20 %) patients were treated with rivaroxaban. In comparison to 1,645 patients on conventional anticoagulation, patients on rivaroxaban were younger (56 \u00b1 18 vs. 65 \u00b1 17 years; p&lt;0.001), less often had pulmonary embolism (38 % vs 66 %; p&lt;0.001), hypertension (26 % vs 41 %; p&lt;0.001), cancer (10 % vs 28 %; p&lt;0.001), congestive heart failure (10 % vs 17 %; p=0.001), diabetes (8 % vs 15 %; p&lt;0.001), chronic lung disease (7 % vs 13 %; p=0.001), renal insufficiency (7 % vs 13 %; p=0.001), recent surgery (7 % vs 14 %; p&lt;0.001), and acute coronary syndrome (1 % vs 4 %; p=0.009). VTE reperfusion therapy was more frequently used (28 % vs 9 %; p&lt;0.001) and indefinite-duration anticoagulation treatment less often planned (26 % vs 39 %; p&lt;0.001), respectively. In the propensity score-adjusted population, the risk of recurrent VTE was similar in patients on rivaroxaban vs conventional anticoagulation (1.2 % vs 2.1 %, hazard ratio [HR] 0.55, 95 % confidence interval [CI] 0.18\u20131.65; p=0.29); the risk of major bleeding was also similar, respectively (0.5 % vs 0.5 %, HR 1.00, 95 %CI 0.14\u20137.07; p=1.00). Conventional anticoagulation is still frequently used for the treatment of VTE, particularly in the elderly and those with comorbidities. Early clinical outcomes were comparable between propensity score-adjusted patient populations on rivaroxaban and conventional anticoagulation.<\/jats:p>","DOI":"10.1160\/th16-03-0209","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T09:07:58Z","timestamp":1467018478000},"page":"472-479","source":"Crossref","is-referenced-by-count":21,"title":["Rivaroxaban for the treatment of venous thromboembolism"],"prefix":"10.1160","volume":"116","author":[{"given":"Drahomir","family":"Aujesky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrg H.","family":"Beer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Mazzolai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Baldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Banyai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hayoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kaeslin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Korte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Escher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Husmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Frauchiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Baumgartner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Spirk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Kucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,11,29]]},"reference":[{"key":"10.1160\/TH16-03-0209-1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906598"},{"key":"10.1160\/TH16-03-0209-2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"10.1160\/TH16-03-0209-3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113572"},{"key":"10.1160\/TH16-03-0209-4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302507"},{"key":"10.1160\/TH16-03-0209-5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306638"},{"key":"10.1160\/TH16-03-0209-6","doi-asserted-by":"crossref","unstructured":"Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database Syst Rev 2015;","DOI":"10.1002\/14651858.CD010956.pub2"},{"key":"10.1160\/TH16-03-0209-7","doi-asserted-by":"crossref","unstructured":"Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database Syst Rev 2015;","DOI":"10.1002\/14651858.CD010957.pub2"},{"key":"10.1160\/TH16-03-0209-8","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12485"},{"key":"10.1160\/TH16-03-0209-9","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2301"},{"key":"10.1160\/TH16-03-0209-10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu243"},{"key":"10.1160\/TH16-03-0209-11","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-11-21"},{"key":"10.1160\/TH16-03-0209-12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563577"},{"key":"10.1160\/TH16-03-0209-13","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00257-4"},{"key":"10.1160\/TH16-03-0209-14","doi-asserted-by":"crossref","unstructured":"Dault R, Vanasse A, Blais L, et al. Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban. Clin Appl Thromb Hemost 2015; Epub ahead of print","DOI":"10.1177\/1076029615611249"},{"key":"10.1160\/TH16-03-0209-15","doi-asserted-by":"crossref","unstructured":"Geldhof V, Vandenbriele C, Verhamme P, et al. Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. Thromb J 2014; Epub ahead of print","DOI":"10.1186\/1477-9560-12-21"},{"key":"10.1160\/TH16-03-0209-16","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.09.039"},{"key":"10.1160\/TH16-03-0209-17","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.11.026"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH16-03-0209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T06:23:37Z","timestamp":1521527017000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH16-03-0209"}},"subtitle":["The SWIss Venous ThromboEmbolism Registry (SWIVTER)"],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":17,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2017,11,11]]},"published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1160\/th16-03-0209","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}